Alprolix® approved in the Kingdom of Saudi Arabia for the treatment of haemophilia B
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix® (eftrenonacog alfa), for the treatment of haemophilia B. Alprolix is the first extended half-life and recombinant factor IX Fc fusion protein therapy approved for the treatment of haemophilia B in Saudi Arabia. “We are very pleased Alprolix is now approved in Saudi Arabia, which will enable physicians to offer their patients with haemophilia B a wider range of treatment options and the opportunity to